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Abstract
Background: Prenatal screening for Down Syndrome (DS) would benefit from an increased number of biomarkers
to improve sensitivity and specificity. Improving sensitivity and specificity would decrease the need for potentially
risky invasive diagnostic procedures.
Results: We have performed an in depth two-dimensional difference gel electrophoresis (2D DIGE) study to
identify potential biomarkers. We have used maternal plasma samples obtained from first and second trimesters
from mothers carrying DS affected fetuses compared with mothers carrying normal fetuses. Plasma samples were
albumin/IgG depleted and expanded pH ranges of pH 4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9 were used for two-
dimensional gel electrophoresis (2DE). We found no differentially expressed proteins in the first trimester between
the two groups. Significant up-regulation of ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain H4,
complement proteins C1s subcomponent, C4-A, C5, and C9 and kininogen 1 were detected in the second
trimester in maternal plasma samples where a DS affected fetus was being carried. However, ceruloplasmin could
not be confirmed as being consistently up-regulated in DS affected pregnancies by Western blotting.
Conclusions: Despite the in depth 2DE approach used in this study the results underline the deficiencies of gel-
based proteomics for detection of plasma biomarkers. Gel-free approaches may be more productive to increase
the number of plasma biomarkers for DS for non-invasive prenatal screening and diagnosis.
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Background
Down Syndrome (or Trisomy 21, DS) is the most com-
mon aneuploidy. According to the National Down Syn-
drome Cytogenetic Register, UK there is an incidence of
~1 in 1600 live births in mothers below the age of 25
which rises to 1 in 40 by age 43. Current diagnosis of
DS occurs via chorionic villus sampling (CVS) (11-14
weeks of gestation) or amniocentesis (15-20 weeks of
gestation); both of which carry a ~1% risk of miscar-
riage. Screening of pregnant women also occurs using a
combination of plasma protein markers, ultrasound
markers and maternal age [1]. Screening markers used
include pregnancy-associated plasma protein A (PAPP-
A), alpha-fetoprotein (AFP) [2], human chorionic gona-
dotropin (hCG and its subunits), the steroid hormone
unconjugated estriol (uE3) and inhibin A [3]. These bio-
m a r k e r sw e r ed i s c o v e r e dm o r eb ya c c i d e n tt h a nac o n -
certed effort to assess markers of DS in maternal
plasma. They are all derived from fetal liver and placen-
tal trophoblast cells. Biochemical testing and ultrasound
assessment can detect 70-96% of DS cases but with a
2.5-5% false positive rate [4-6].
Non-invasive prenatal diagnosis (NIPD) (and screen-
ing) would remove the risk of miscarriage associated
with amniocentesis and CVS (see [7] for an NIPD
review). With the improved technical approaches now
available in the field of proteomics, there is potential to
discover new panels of screening biomarkers [8]. The
identification of a panel of more informative DS markers
was a major goal of the European Framework VI SAFE
Network of Excellence [9-15]. Proteomics, with a variety
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studies to define new potential biomarkers for aneuploid
pregnancies [11,12,16-20]. Maternal plasma was used in
half of these studies [11,12,17] and amniotic fluid in the
others [16,18-20]. Five studies analysed samples from
the second trimester [11,16,18-20], Kolla et al. [12] ana-
lysed samples from the first trimester and Nagalla et al.
[17] analysed samples from both the first and second
trimesters. A mother will be better informed, and have
more choices available to her, if a potential biomarker
can be used as early as possible in prenatal screening
and/or diagnosis but if the expression of a biomarker is
altered throughout gestation, it will give increased uti-
lity. Detection rates are higher for DS and false positive
rates are lower in the first trimester than the second tri-
mester [5,6] so the identification of new and better bio-
markers for the second trimester is of paramount
importance.
In the present study, 2D DIGE [21] has been used to
search for potential plasma DS biomarkers. We have
compared maternal plasma from women carrying either
normal or DS fetuses from first and second trimesters.
We have used three overlapping pH ranges (pH 4.5 -
5.5, pH 5.3 - 6.5 and pH 6 - 9) for 2DE which improves
the resolution of previous studies (pH 3 - 10 [11] and
pH 4 - 7 [17]). Protein identification from 2D gels was
done by mass spectrometry.
Results
2D DIGE Experiments
Plasma samples from pregnancies with DS and chromo-
somally normal fetuses were analysed using 2D DIGE.
Three overlapping pH ranges were used for 2DE - pH
4.5 - 5.5, pH 5.3 - 6.5 and pH 6 - 9. Protein spots were
detected, analysed and compared using Progenesis Same
Spots and DeCyder v6.5 software. Statistically significant
differences between expression of proteins in DS sam-
ples compared to euploid (control, Ctl) samples are
shown (Table 1). Following the detection of differences,
protein identifications of picked spots were determined
by mass spectrometry.
4.5 - 5.5 pH range
Two sets of 7 paired samples were tested for the 4.5 -
5.5 pH range for the first trimester, giving a total of 14
gestationally age-matched pairs of Ctl and DS samples.
With the first 7 pairs of samples, there were up to 13
protein spots differentially expressed between DS and
Ctl samples, depending on the software analysis package
used. Only two protein spots matched between the ana-
lyses with Progenesis Same Spots and DeCyder v6.5,
highlighting the differences in algorithms used. With the
second set of 7 pairs of DS and Ctl matched samples,
none of the initial spots could be confirmed as differen-
tially expressed. It was concluded that there were no
differentially expressed proteins in this pH range for
first trimester samples.
For the second trimester, eight pairs of age-matched
DS and Ctl samples were subjected to 2D DIGE over
the pH 4.5 - 5.5 range. Figure 1 shows a representative
2D gel image with the differentially expressed proteins
between the two groups highlighted, whilst Figure 2
gives a 3D representation of the ceruloplasmin protein
spots. Table 1 summarizes the spot number, symbol,
Swiss-Prot accession number, theoretical pI, molecular
weight, score, number of peptides used for identification
and protein coverage for the differentially expressed
proteins. The proteins shown are those that matched
from the two software analyses. Seven proteins showed
up-regulation in DS versus Ctl samples - ceruloplasmin,
inter-alpha-trypsin inhibitor heavy chain H4, comple-
ment proteins C1s subcomponent, C4-A, C5, and C9
and kininogen 1.
5.3 - 6.5 pH range
14 pairs of samples from the first trimester were ana-
lysed for the pH range 5.3 - 6.5. No protein spots were
found to be differentially expressed between DS samples
and Ctl samples with more than 1.5 fold up- or down-
regulation and both software packages. This was also
the case for the second trimester samples.
6 - 9 pH range
All 14 pairs of samples from the first trimester were
analysed by 2D DIGE for the pH 6 - 9 range. No protein
spots were altered by ≥1.5 fold in DS samples compared
to Ctl samples by both software packages.
2D DIGE data from 9 pairs of DS and Ctl samples
from the second trimester led to the conclusion that
one protein spot was differentially expressed between
DS and Ctl groups (marked A in Figure 3). However,
identification of this protein proved elusive, mainly ham-
pered by an excess of serotransferrin in the same region.
Confirmatory Experiments
Previous studies [11,17] have shown an increase in the
levels of ceruloplasmin in DS samples compared to Ctl
samples in first and second trimesters. In our 2D DIGE
experiments, we confirmed this change in the second
but not the first trimester. We assessed whether the dif-
ference in ceruloplasmin protein expression between DS
and Ctl samples could be detectable with an anti-cerulo-
plasmin mAb and conventional 1D Western blotting.
After using a CyDye-conjugated secondary antibody and
ImageQuant software v5.2, we detected no statistically
significant difference between the expression levels of
ceruloplasmin in the two sample groups (Figure 4).
Discussion
At present, diagnosis of DS involves the invasive techni-
ques of amniocentesis and CVS. There have been
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Page 2 of 10Table 1 Proteins differentially expressed in the second trimester in the pH range 4.5 - 5.5
Spot
no.
(as on
Figure
1)
Accession
number
(Swiss-
Prot)
Abbreviated
name
Protein name Average
fold up-
regulation
(DS/Ctl)
Theoretical
mW (Da)
Theoretical
pI
Scores for
individual
spot
identifications
Number of
sequenced
peptides
Peptide
positions
within
the
protein
Peptides sequenced
(overlap between spots
identified per protein)
Coverage
(%) (Total
number
of
peptides
assigned
to
protein)
Function
1 P00450 Ceruloplasmin
(Seven spots
identified for
this protein)
CERU_HUMAN 3.69 122205 5.44 173, 437, 431,
460, 331, 107,
110
8, 17, 16,
15, 12, 7, 7
42 - 63
43 - 63
69 - 82
187 - 202
248 - 259
426 - 437
468 - 482
484 - 501
523 - 538
537 - 548
537 - 559
547 - 559
598 - 610
598 - 620
720 - 733
785 - 794
798 - 820
887 - 902
944 - 958
K.KLISVDTEHSNIYLQNGPDR.I
K.LISVDTEHSNIYLQNGPDR.I
K.ALYLQYTDETFR.T
K.DIASGLIGPLIICK.K
K.DNEDFQESNR.M
R.EYTDASFTNR.K
K.GAYPLSIEPIGVR.F
K.NNEGTYYSPNYNPQSR.S
K.EVGPTNADPVCLAK.M
K.MYYSAVDPTK.D
K.MYYSAVDPTKDIFTGLIGPMK.I
K.DIFTGLIGPMK.I
R.MFTTAPDQVDK.E
R.MFTTAPDQVDKEDEDFQESNK.M
R.QSEDSTFYLGER.T
R.QYTDSTFR.V
R.KAEEEHLGILGPQLHADVGDK.V
K.DLYSGLIGPLIVCR.R
K.VNKDDEEFIESNK.M
20.6 (19) Copper-binding
glycoprotein,
ferroxidase activity,
iron transport
2 Q14624 inter-alpha
trypsin
inhibitor heavy
chain H4
ITIH4_HUMAN 2.11 103357 6.51 74 10 98 - 112
152 - 163
214 - 225
299 - 308
428 - 439
500 - 513
633 - 645
657 - 670
815 - 827
831 - 843
K.AEAQAQYSAAVAK.G
R.RLGVYELLLK.V
R.FKPTLSQQQK.S
K.ILDDLSPR.D
K.LALDNGGLAR.R
R.GPDVLTATVSGK.L
K.IPKPEASFSPR.R
R.MNFRPGVLSSR.L
K.ETLFSVMPGLK.M
K.TGLLLLSDPDK.V
11.5 (10) Serine-type
endopeptidase
inhibitor, acute-
phase response,
hyaluronan
metabolic process
3 P0C0L4 complement
C4-A precursor
(Two spots
identified for
this protein)
CO4A_HUMAN 2.61 192771 6.66 192, 93 8, 4 756 - 776
916 - 930
979 -
1006
1042 -
1052
1084 -
1100
1291 -
1301
1340 -
1350
1352 -
1366
R.ALEILQEEDLIDEDDIPVR.S
R.GSFEFPVGDAVSK.V
R.
VTASDPLDTLGSEGALSPGGVASLLR.
L
K.DHAVDLIQK.G
K.VLSLAQEQVGGSPEK.L
R.QGSFQGGFR.S
K.SHALQLNNR.Q
R.GLEEELQFSLGSK.I
6.5 (8) Activation of the
classical pathway of
the complement
system
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0Table 1 Proteins differentially expressed in the second trimester in the pH range 4.5 - 5.5 (Continued)
4 P01031 complement
C5 precursor
CO5_HUMAN 1.59 188305 6.11 154 6 78 - 91
308 - 322
353 - 373
436 - 450
495 - 507
622 - 630
K.FQNSAILTIQPK.Q
K.ELSYYSLEDLNNK.Y
K.LNLVATPLFLKPGIPYPIK.V
K.TDAPDLPEENQAR.E
K.ITHYNYLILSK.G
R.VFQFLEK.S
4.5 (6) Complement
cascade through to
formation of
membrane attack
complex (MAC),
inflammatory
response
5 P02748 complement
component C9
precursor
CO9_HUMAN 2.38 63173 5.43 196 7 65 - 77
144 - 155
145 - 155
231 - 243
472 - 484
496 - 509
533 - 544
R.SIEVFGQFNGK.R
R.DRVVEESELAR.T
R.VVEESELAR.T
K.TSNFNAAISLK.F
K.LSPIYNLVPVK.M
R.AIEDYINEFSVR.K
K.FEGIACEISK.Q
11.8 (7) Pore-forming
subunit of the MAC
that plays a key
role in the innate
and adaptive
immune response
6 P01042 kininogen-1
(Two spots
identified for
this protein)
KNG1_HUMAN 1.72 71957 6.34 37, 187 6, 9 43 - 59
64 - 76
101 - 114
187 - 197
208 - 220
240 - 255
254 - 263
316 - 325
380 - 390
K.YNSQNQSNNQFVLYR.I
K.TVGSDTFYSFK.Y
K.AATGECTATVGK.R
R.QVVAGLNFR.I
K.ENFLFLTPDCK.S
R.IASFSQNCDIYPGK.D
K.DFVQPPTK.I
K.YFIDFVAR.E
K.RPPGFSPFR.S
15.1 (9) Role in blood
coagulation,
inhibitor of thiol
proteases,
inflammatory
response, diuresis
and natriuresis,
smooth muscle
contraction,
negative regulation
of cell adhesion
7 P09871 complement
C1s
subcomponent
precursor
(Three spots
identified for
this protein)
C1S_HUMAN 4.45 76684 4.86 190, 66 8, 5, 6 86 - 106
264 - 281
314 - 332
369 - 384
481 - 497
515 - 524
523 - 535
629 - 645
677 - 688
R.SSNNPHSPIVEEFQVPYNK.L
K.SNALDIIFQTDLTGQK.K
R.DVVQITCLDGFEVVEGR.V
K.VEDPESTLFGSVIR.Y
R.EPTMYVGSTSVQTSR.L
K.LLEVPEGR.T
R.TNFDNDIALVR.L
K.GDSGGAFAVQDPNDK.T
K.TMQENSTPRED.-
18.3 (9) Serine-type
endopeptidase
involved in
activation of
classical pathway of
the complement
system
The table shows those proteins that are differentially expressed between DS and Ctl pregnancies in the second trimester in the pH range 4.5 - 5.5. All results displayed here are from ESI Q-TOF MS/MS analysis.
Identified proteins are given with UniProt accession number, average fold up-regulation in DS samples compared to Ctl samples (from DeCyder analysis; comparable to Progenesis), theoretical molecular weight and
pI (calculated using the Compute pI/mW function available on the ExPASy website, full amino acid sequence used including signal peptides), search score and number of peptides used for identification. The
sequences of the peptides used for the identification of the protein spots (M indicates methionine oxidation) and their position within the protein sequence are shown; also the function of the protein. Coverage
indicates the percentage of the residues in each protein sequence that was identified. Score is -10*Log(P), where P is the probability that the observed match is a random event. Scores > 46 indicate identity or
extensive homology at the p < 0.05 level.
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0significant advances in NIPD for DS in recent years
including the assessment of free fetal DNA in maternal
plasma using next generation sequencing [22-26]. How-
ever, this is an expensive technique so there is still
scope for the use of new plasma biomarkers for prenatal
screening.
This study focused in more depth on the depleted
maternal plasma proteome for DS biomarkers than pre-
vious studies by investigating expanded pH ranges for
2D DIGE. This approach achieves better separation and
resolution of proteins, giving greater analysis of differen-
tial expression. Broader range pH gels have overlapping
protein separations making accurate quantification diffi-
cult and obscuring low abundance proteins. In this
study, no significant differential protein expression was
observed in the first trimester. In the second trimester,
protein changes detected in maternal plasma in the pH
4.5 - 5.5 range included increased levels of ceruloplas-
min, inter-alpha-trypsin inhibitor heavy chain H4, com-
plement proteins C1s subcomponent, C4-A, C5, and C9
and kininogen 1 in DS samples. Some of these changes
correspond to those found by other groups [11,17,18]
(ceruloplasmin, inter-alpha-trypsin inhibitor heavy chain
H4, complement component C9 and kininogen 1). One
of the greatest changes in the current study was in ceru-
loplasmin protein expression - 3.69 fold up-regulated in
DS - a larger fold change than seen by other groups.
However, when ceruloplasmin levels were specifically
assessed by Western blotting, no significant difference
could be seen between samples. This was most likely
Figure 1 Representative 2D DIGE gel of second trimester
maternal plasma in pH 4.5 - 5.5 range. Image shown is from Cy2
signal. Spots numbered are those shown to be significantly
differentially expressed in DS samples by more than 1.5 fold (p <
0.05) compared with controls. Eight gels were run (DS [n = 8] and
Ctl [n = 8]). See Table 1 for mass spectrometry-based identifications.
1 = ceruloplasmin, 2 = inter-alpha-trypsin inhibitor heavy chain H4,
3 = complement C4-A precursor, 4 = complement C5 precursor, 5 =
complement component C9 precursor, 6 = kininogen-1, 7 =
complement C1s subcomponent precursor
Figure 2 3D representation of volume of ceruloplasmin protein
spots on 2D DIGE gel. Representation is for pH 4.5 - 5.5 range for
second trimester samples. A) Ctl protein spots; B) DS protein spots.
Figure 3 Representative 2D DIGE gel of second trimester
maternal plasma in pH 6 - 9 range. Image shown from Cy2 signal.
Spot A is significantly up-regulated in DS samples by more than 1.5
fold (p < 0.05) compared with Ctl samples. Protein was unable to be
identified. Nine gels were run (DS [n = 9] and Ctl [n = 9]).
Figure 4 Representative 1D Western blot for anti-ceruloplasmin
expression. Second trimester maternal plasma samples were used
(in total, DS [n = 10] and Ctl [n = 10]). Equal amounts of plasma from
all samples were separated by gel electrophoresis and blotted with
the appropriate dilution of antibody (refer to Materials and Methods).
A standard control sample (labelled as ‘Standard’) was selected and
run on every blot to use as a calibration. No significant difference
was seen between DS and Ctl levels of ceruloplasmin (CERU; running
on 1D gel at 132 kDa).
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Page 5 of 10due to the fact that Western blotting is only semi-quan-
titative. The epitope of ceruloplasmin that the primary
antibody was designed against is unknown and hence
changes between DS and Ctl samples may be detected
b yt h eu s eo fad i f f e r e n tp r i m a r ya n t i b o d y .C e r u l o p l a s -
m i ni ss e e na st w oc h a i n so fs p o t sw i t h2 DD I G Ea n d
the changes detected may be a change in post-transla-
tional modification of the protein as well as total level
of protein. The more stringent 2D DIGE approach of
the current study did not corroborate many of the pre-
vious findings by other groups [11,17], who have per-
formed 2DE using a broader pH range. Differences in
method (including study size) and sample preparation
(including collection, processing and storage) may con-
tribute to discrepancies. We have compared all known
mass spectrometry-based 2DE based proteomic identifi-
cations of DS plasma markers (see Additional file 1,
Table S1).
The potential biomarkers highlighted here are
involved with fetal growth and development. Ceruloplas-
min transports copper and ceruloplasmin levels increase
during pregnancy. The impaired transport of copper has
been associated with poor pregnancy outcome [27,28].
Increased ceruloplasmin levels have been detected in
postmortem brain samples from patients with a variety
of neurodegenerative diseases [29], implicating a possi-
ble change in oxidative stress in regions of the brain.
However, Tórsdóttir et al. [30] showed there was no
change in ceruloplasmin oxidative activity that could be
correlated with dementia in DS. In a recent study using
a redox proteomics approach, ceruloplasmin was shown
to be increasingly carbonylated in DS amniotic fluid
samples [20]. Inter-alpha-trypsin inhibitor heavy chain
H4 levels were also shown to be increased in DS in this
study. This is a plasma glycoprotein, which is primarily
expressed in the liver and can act as an acute-phase pro-
tein in several species. It acts as a substrate for plasma
peptidase kallikrein [31] but its exact role in vivo
remains unclear. Four of the proteins shown to be up-
regulated in DS samples belong to the complement sys-
tem. Perluigi et al. [20] suggest that increased levels of
the oxidized form of complement C9 may lead to a loss
of biological function, altering its role in the acute-phase
response protecting the developing fetus. Kininogen 1
was shown to be up-regulated in DS samples in this
study. This protein has a role to play in the blood coa-
gulation system, as well as the kinin-kallikrein system.
Kininogen was also found to be oxidized in DS amniotic
fluid [20].
In women bearing DS fetuses placental development is
often abnormal [32]. The process of cytotrophoblast
fusion to form syncytiotrophoblast does not occur prop-
erly [33]. Defective placental development may result in
an elevated level of placental debris [12]. Several of the
peptides identified in the current study are likely to be
fragments of the larger full-length proteins, given that
the molecular weight and pI of the intact proteins (see
Table 1) do not always agree with the location of the
protein spots on the 2D gels (see Figure 1). This implies
enzymatic activity in the plasma samples resulting in the
cleavage of the proteins.
The genes encoding the proteins that have been shown
to be differentially expressed between DS and Ctl sam-
ples in this study are located on chromosomes other than
chromosome 21. This implies that proteins encoded by
genes located on chromosome 21 (such as transcription
factors) are influencing the expression of genes on other
chromosomes. The current study did not detect changes
in expression in the current protein screening markers
(PAPP-A, AFP, hCG, inhibin A) between DS and Ctl
samples. This was also the case in other 2DE studies
[11,17] but two groups [12,19] detected an increase in
beta hCG in DS samples, suggesting that there is an
increase in sensitivity in iTRAQ analysis and 2D LC-MS/
MS analysis versus a 2D gel approach. Another reason
for the lack of detection of the current screening markers
is that some proteins are more amenable to being
detected by mass spectrometry than others.
Proteomic methods have also been applied for the
identification of biomarkers in other fetal aneuploidies -
Turner Syndrome (XO karyotype) [34,35] and Klinefel-
ter syndrome (XXY karyotype) [36]. Most of the bio-
markers identified in these studies also show changes in
expression in DS, indicating they are not specific to an
extra copy of chromosome 21 (this paper; [11,12,17]).
A recent study has used integrative data mining as an
approach to try to identify biomarkers for DS screening
[37]. Also bead-based multiplexed immunoassays have
identified new DS biomarkers [38] and epidermal
growth factor was confirmed as a potential biomarker
following a validation study [39]. Lopez et al. performed
selective reaction monitoring following mass spectrome-
try biomarker discovery, thus developing high through-
put robust assays for DS detection [40].
Conclusion
This study has shown the up-regulation of seven protein
biomarkers in the maternal plasma of DS pregnancies
compared to Ctl pregnancies in the second trimester of
pregnancy, with overlap between these identified bio-
markers and previous studies. These markers need to be
assessed in a larger cohort of pregnancies and in the
w i d e rp o p u l a t i o nb e f o r et h e yc o u l dp o t e n t i a l l yb eu s e d
as better screening markers and/or for diagnosis. Given
such an extensive study of different pH ranges, to find
only seven altered proteins is surprising. However, it
must be appreciated that gel-based approaches for pro-
tein identification are limited. Gel-free-based approaches
Heywood et al. Proteome Science 2011, 9:56
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Page 6 of 10may be more informative. There is scope for improve-
ment in the current screening protocols and further
work needs to be done to detect and diagnose DS in the
first trimester non-invasively. The ultimate goal remains
the introduction of NIPD tests that are rapid, inexpen-
sive, automated and accurate.
Methods
Materials
Maternal peripheral blood (in EDTA tubes) was taken
with informed consent from pregnant women (majority
of women of Caucasian background) attending the Fetal
Medicine Unit, University College Hospital, London, U.
K. for invasive diagnostic testing for a range of clinical
indications as part of the SAFE Framework 6 Network
of Excellence study [9]. Fourteen blood samples were
obtained from normal pregnancies (Ctl) and 14 from DS
affected pregnancies in the 10-14 week (wk) gestation
period (first trimester) (average difference in gestational
age between matched samples 3.5 days). The DS status
was determined by karyotype analysis from CVS or
amniotic fluid at University College Hospital, London. A
similar number of samples were obtained in the 14-28
wk gestation period (second trimester) (average differ-
ence in gestational age between matched samples 10.5
days). Samples were analysed independently (hence pro-
viding fourteen potential biological replicates per trime-
ster, see Additional file 2, Table S2 to see how Ctl and
DS samples were matched as pairs). Maternal age ran-
ged from 21-45 years for Ctl pregnancies and from 19-
42 years for DS affected pregnancies (average maternal
age Ctl pregnancies first trimester 35.4 years, average
maternal age DS affected pregnancies first trimester 36.3
years, average maternal age Ctl pregnancies second tri-
mester 35 years, average maternal age DS affected preg-
nancies second trimester 36.1 years, no significant
difference between Ctl and DS groups for either trime-
ster). Plasma was obtained by centrifuging the blood
samples at 1,500 g for 10 minutes (min) and further
separated by centrifuging at 16,000 g for 15 min. Pro-
tease inhibitor cocktail (Sigma-Aldrich, Dorset, U.K.)
was added and fractions were stored at -80°C prior to
analysis. 55 of 56 samples were processed within 24
hours (hrs) of collection, with 40 of these being pro-
cessed within 8 hrs of collection (no significant differ-
ence between processing of Ctl and DS samples).
Collection of samples took place from January 2006 to
June 2007 and samples were analysed by 2D DIGE dur-
ing this period and up to March 2008.
Methods
Sample Preparation
Plasma samples were depleted for albumin and IgG
using the Qproteome Albumin/IgG Depletion Kit
(QIAGEN, Crawley, U.K.). Depleted protein was eluted
into 50 mM ammonium bicarbonate buffer pH 7.8 and
assayed for protein concentration using the Bicconinic
acid kit (Sigma-Aldrich, Dorset, U.K.) or samples were
eluted into 50 mM Tris Cl; 4% w/v CHAPS; 200 mM
urea, pH 7.5 and cleaned up for 2DE using the 2D
Clean-Up Kit (GE Healthcare, Little Chalfont, U.K.).
The latter samples were assayed for protein concentra-
tion using the NanoOrange
® Protein Quantitation Kit
(Invitrogen, Paisley, U.K,). Protein was aliquoted to
required amounts, frozen or freeze dried.
2D DIGE and Image analysis
Depleted plasma protein samples (30 μg) were re-sus-
pended in labelling buffer (7 M Urea, 2 M Thiourea, 2%
w/v CHAPS, 10-20 mM Tris) and labelled with CyDye
DIGE Fluor minimal dyes (GE Healthcare, Little Chal-
font, U.K.) (reconstituted in fresh 99.8% anhydrous
DMF) at a concentration of 400 pmol of dye/50 μgo f
protein. Ctl samples were labelled with Cy3 and DS
samples were labelled with Cy5 or vice versa and a stan-
dard pool consisting of protein from all samples was
labelled with Cy2. Labelling reactions were halted with
10 μM lysine (Sigma-Aldrich, Dorset, U.K.). All three
labelled samples were combined and resolved in one gel.
CyDye labelling of Ctl and DS samples was mixed
equally. Combined samples were added to IPG strip
rehydration buffer (7 M Urea, 2 M Thiourea, 2% w/v
CHAPS, 50 mM DTE and 0.5-1% v/v relevant IPG buf-
fer) and applied to either pH 4.5 - 5.5, pH 5.3 - 6.5 or
pH 6 - 9 24 cm immobiline drystrips (GE Healthcare,
Little Chalfont, U.K.), covered with mineral oil and left
at room temperature for 12-24 hrs. Drystrips were run
on an IPG Multiphor (GE Healthcare, Little Chalfont,
U.K.) for a total of 90-100,000 Vh with a 50 μA/drystrip
limit. Strips were incubated for 15 min each in 10 mg/
mL DTE equilibration buffer and then 25 mg/mL iodoa-
cetamide equilibration buffer and resolved on 12% acry-
lamide gels, using piperidinediacrylamide (Bio-Rad,
Hemel Hempstead, U.K.) as a crosslinker. Gels were run
in a Hoefer DALT tank using the Ettan DALT electro-
phoresis system (GE Healthcare, Little Chalfont, U.K.).
Gels were scanned on a Typhoon 9400 Variable Mode
Imager (GE Healthcare, Little Chalfont, U.K.) at a reso-
lution of 100 μm. 2D gel images were analysed for dif-
ferentially expressed spots using Progenesis SameSpots
software version 3.1 (Nonlinear Dynamics Ltd, Newcas-
tle upon Tyne, U.K.) or DeCyder v6.5 (GE Healthcare,
Little Chalfont, U.K.), following protein spots being
detected, aligned and matched between gels. Normalized
protein spots in the Cy5 and Cy3 channels were com-
pared to the internal standard (Cy2) to generate a ratio
of relative amount. Ctl and DS samples were compared
using Student’s t test analysis. A threshold level was set
of 1.5 fold up- or down-regulation, at p < 0.05 level.
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12% bis acrylamide preparative 2D gels were run with
1.5 mg of pooled depleted freeze dried plasma protein.
Gels were either colloidal Coomassie blue (Sigma-
Aldrich, Dorset, U.K.) or silver stained and spots trypsin
digested for MALDI-TOF analysis according to pre-
viously described methods [41,42]. Following tryptic
digestion, peptides were extracted in 50% v/v ACN/0.1%
v/v TFA and spotted with 1:1 ratio of 10 mg/mL alpha-
cyano-4-hydroxycinnamic acid in 50:50 v/v methanol/
ACN. Samples were analysed using a MALDI-TOF mass
spectrometer (Waters-Micromass, Elstree, U.K.), as pre-
viously described [42].
Some samples were analysed using a Waters Q-TOF
Micro mass spectrometer (Waters-Micromass, Elstree,
U.K.) to obtain nanoelectrospray ionization tandem
mass spectra. Samples were separated on a Dionex Ulti-
mate 1 nanoflow-LC system (Dionex, Camberley, U.K.)
using a 15 cm × 0.75 mm Acclaim PepMap100 C18 3
μm column with a flow rate of 200 nL/min. Solvent A
was 5% v/v ACN/95% v/v 0.1% v/v aqueous formic acid
and solvent B was 80% v/v ACN/20% v/v 0.1% v/v aqu-
eous formic acid and a gradient time of 60 min was
used. MS/MS spectra were acquired in data-dependent
mode, processed using ProteinLynx Global Server v.2.1
software and then protein identities confirmed using
MASCOT (SwissProt database version 55.4 [385721
sequences] to version 56.0 [392667 sequences]) (Matrix
Science Ltd., London, U.K.). Search criteria were: pep-
tide tolerance of 100 parts per million (ppm); fragment
tolerance of 0.1Da; two trypsin missed cleavages per
peptide; fixed carbamidomethylation of cysteine and
variable oxidation of methionine modifications. Only
identities from MASCOT with three or more peptides
were considered.
As several peptides from a protein were identified
from different Q-TOF analyses, Protein Coverage Sum-
marizer software [43] was used to determine the percen-
tage of the residues in each protein sequence that was
identified (coverage column in Table 1).
Western Blot analysis
Plasma samples were diluted in PBS and the equivalent
of 0.75 μL of plasma were separated by 4-12% gradient
reducing SDS-PAGE. A standard control sample was
run on every blot to use as a calibration. Ten different
DS samples and 10 different Ctl samples were run and
proteins were blotted onto Hybond-LFP PVDF mem-
brane (GE Healthcare, Little Chalfont, U.K.). Blots were
blocked for 1 hr in 2% w/v ECL Advance Block (GE
Healthcare, Little Chalfont, U.K.) in PBS/1% v/v Tween
20. Membranes were incubated overnight at 4°C with
1:1000 dilution of mouse mAb to ceruloplasmin (SC-
69767; Santa Cruz, Germany) (in blocking buffer). Blots
were washed 6 x10 min with 0.1% v/v Tween 20 in PBS
before being incubated for 1 hr with anti-mouse Cy3
conjugated secondary antibody (GE Healthcare, Little
Chalfont, U.K.) at a 1:2500 dilution. Blots were washed
and dried overnight in the dark then scanned for Cy3
dye fluorescence using a Typhoon 9400 Variable Mode
Imager. ImageQuant software v5.2 (Molecular
Dynamics, U.K.) was used to measure volume, back-
ground intensity was subtracted, every blot was run in
triplicate and intensity was calibrated and averaged for
each sample. Statistical analysis was performed using
Microsoft Excel 2003 software. Student’s t-test was used
to test for significance between the protein levels in Ctl
versus DS maternal plasma samples.
Additional material
Additional file 1: Potential biomarkers for DS identified by mass
spectrometry-based 2DE-based proteomic studies. In Table S1, we
have compared all known mass spectrometry-based 2DE-based
proteomic identifications of DS plasma markers.
Additional file 2: Clinical and demographic data for maternal
peripheral blood samples. In Table S2, all relevant information about
the Ctl/DS sample pairs for the first and second trimesters is detailed.
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